Citius Oncology, Inc. (CTOR) Quick Ratio
- Quick ratio · latest quarter: Value (m); Formula and calculation Cash, cash equivalents, current marketable securities and trade receivables / current liabilities. Period ending 2026-06-30..
Quick ratio
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Quick ratio · latest quarter | (m) | Cash, cash equivalents, current marketable securities and trade receivables / current liabilities. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Cash, securities and trade receivables | (m) | Cash and Cash Equivalents, at Carrying Value · Accounts Receivable, after Allowance for Credit Loss, Current |
| Current obligations | 58.79M USD | Liabilities, Current |
| Cash and equivalents | 16.56M USD | Cash and Cash Equivalents, at Carrying Value |
| Short-term securities | (m) | |
| Customer receivables | 686.24K USD | Accounts Receivable, after Allowance for Credit Loss, Current |
| Inventory · excluded from quick assets | 22.63M USD | Inventory, Net |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Cash, securities and trade receivables (USD) | Current obligations (USD) | Cash and equivalents (USD) | Short-term securities (USD) | Customer receivables (USD) | Inventory · excluded from quick assets (USD) | Quick ratio |
|---|---|---|---|---|---|---|---|
| 2026-06-30 | (m) | $58.79M | $16.56M | (m) | $686.24K | $22.63M | (m) |
| 2026-03-31 | (m) | $58.81M | $2.63M | (m) | $1.08M | $22.66M | (m) |
| 2025-12-31 | (m) | $44.71M | $7.30M | (m) | $4.05M | $22.64M | (m) |
| 2025-09-30 | (m) | $49.49M | (m) | (m) | (m) | $22.29M | (m) |
| 2025-06-30 | (m) | $52.99M | $112.00 | (m) | (m) | $17.21M | (m) |
| 2025-03-31 | (m) | $49.74M | $112.00 | (m) | (m) | $15.34M | (m) |
| 2024-12-31 | (m) | $43.40M | (m) | (m) | (m) | $14.38M | (m) |
| 2024-09-30 | (m) | $32.70M | (m) | (m) | (m) | $8.27M | (m) |
| 2024-06-30 | (m) | $3.08M | (m) | (m) | (m) | (m) | (m) |
| 2024-03-31 | (m) | $2.82M | (m) | (m) | (m) | (m) | (m) |
| 2023-12-31 | (m) | $2.05M | (m) | (m) | (m) | (m) | (m) |
| 2023-09-30 | (m) | $1.17M | (m) | (m) | (m) | (m) | (m) |
| 2023-06-30 | (m) | $463.88K | (m) | (m) | (m) | (m) | (m) |
| 2023-03-31 | (m) | $47.78K | (m) | (m) | (m) | (m) | (m) |
| 2022-12-31 | (m) | $31.84K | (m) | (m) | (m) | (m) | (m) |
| 2022-09-30 | (m) | $266.86K | (m) | (m) | (m) | (m) | (m) |
| 2021-12-31 | (m) | $136.53K | (m) | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Anixa Biosciences Inc (ANIX) | United States | $0.096B | |
| Milestone Pharmaceuticals Inc. (MIST) | $0.098B | -2.00 | |
| ProMIS Neurosciences Inc. (PMN) | $0.102B | ||
| Acrivon Therapeutics, Inc. (ACRV) | United States | $0.091B | -1.03 |
| Rallybio Corp (RLYB) | United States | $0.089B | |
| Polaryx Therapeutics, Inc. (PLYX) | United States | $0.106B | |
| ONCOLYTICS BIOTECH INC (ONCY) | $0.086B | ||
| Biomea Fusion, Inc. (BMEA) | United States | $0.107B | -3.30 |
| NEONC TECHNOLOGIES HOLDINGS, INC. (NTHI) | United States | $0.086B | |
| Equillium, Inc. (EQ) | United States | $0.109B | -11.27 |